# Conopco Inc. d/b/a Unilever – FDA 483, Jul 13, 2026

Source: https://www.keypedia.com/records/483/conopco-inc-dba-unilever/3337f69a-17ac-49c1-9272-4aa16bb8f157

> FDA 483 for Conopco Inc. d/b/a Unilever on July 13, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Conopco Inc. d/b/a Unilever
- Inspection Date: 2026-07-13
- Product Type: drugs
- Office Name: Atlanta District Office
- Summary: An FDA inspection of Conopco Inc. d/b/a Unilever in Raeford, NC, a drug manufacturer, revealed significant deficiencies in quality control, equipment maintenance, and record-keeping. The firm failed to adequately investigate consumer complaints and deviations, maintain equipment in good repair, establish proper cleaning validation procedures, and keep comprehensive equipment logs. These issues indicate a systemic lack of adherence to good manufacturing practices, posing potential risks to drug product quality and safety.

## Related Officers

- [Michael Z. Weigman](https://www.keypedia.com/people/michael-z-weigman/fcf79bb1-87cc-476c-a1af-758ef0126ee9)

Company: https://www.keypedia.com/companies/conopco-inc-dba-unilever/f742261e-b37a-43b6-afd4-98d63b24d0da

Office: https://www.keypedia.com/offices/atlanta-district-office/7586d99a-288e-49d1-8c3d-d88b7354b7a7